http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : 손병석 ( Byeong Seok Sohn ) (검색결과 6 건)
- 무료
- 기관 내 무료
- 유료
-
손병석,Byeong Seok Sohn 대한소화기암연구학회 2022 Journal of digestive cancer reports Vol.10 No.1
Immune checkpoint inhibition has been established as a new treatment option for various types of carcinoma, and many clinical trials are being actively conducted as a treatment for advanced or metastatic gastric cancer, either as a monotherapy with an immune checkpoint inhibitor or as a combination therapy with standard chemotherapy. In the CheckMate-649 clinical trial to confirm the efficacy of the combination of nivolumab and chemotherapy (FP) in advanced gastric cancer and gastroesophageal junction cancer, nivolumab group showed improvement in overall survival in programmed death ligand 1-positive cancer patients compared with placebo group. Also, the combination therapy of pembrolizumab, trastuzumab and chemotherapy (FP) in first-line treatment was tested through the KEYNOTE-811 trial. The pembrolizumab group showed 22.7% of improvement in objective response rate compared with placebo group. Accordingly, the combination of nivolumab/pembrolizumab with standard chemotherapy was approved for the first-line treatment. In KEYNOTE-059 trials for patients with progressive disease after at least two lines of chemotherapy, pembrolizumab monotherapy showed improvement in objective response rate and overall survival, and the use of pembrolizumab was approved for the third-line or more treatment. In this article, we review the result of clinical trials related to immune checkpoint inhibitors that have been recently introduced in the treatment of gastric cancer.
-
재발성 췌장염으로 발현한 췌장 상피내 종양(PanIN-3) 1예
손병석 ( Byeong Seok Sohn ),이성구 ( Sung Koo Lee ),김명환 ( Myung Hwan Kim ),서동완 ( Dong Wan Seo ),이상수 ( Sang Soo Lee ),김송철 ( Song Cheol Kim ),장세진 ( Sae Jin Jang ) 대한내과학회 2008 대한내과학회지 Vol.74 No.3
췌장 상피내 종양은 전암성 병변으로, 췌장암의 조기 진단 가능성 및 치료에 대한 기대로 인해 관심을 받고 있다. 췌장 상피내 종양은 원칙적으로 현미경 소견 이외에는 확인할 방법이 없으나, 최근 췌장 상피내 종양이 흔히 췌관 협착을 동반한 섬유화와 함께 발견되는 예가 보고되고 있어 이를 통한 조기 진단에 기대를 모으고 있다. 본례에서는 췌장 체부에 국소 만성 췌장염에 의한 섬유화 종괴의 발생과 이 종괴에 의한 재발성 췌장염 증상으로 내원하여 수술적 치료 시행하고, 병리 소견에서 섬유화 종괴 내에서 췌장 상피내 종양(PanIN-III)을 확인한 1예를 보고한다. Acute recurrent pancreatitis has a variety of etiologies. We experienced a case of a tumor-forming pancreatitis in a 49 year old Korean woman who also had pancreatic intraepithelial neoplasm III (PanIN-III), and this manifested just like recurrent pancreatitis. She had a history of recurrent pancreatitis. She was found to have an early stage of pancreatic cancer via computed tomography and magnetic resonance cholangiopancreatography. EUS guided fine needle aspiration (FNA) showed only many acinar cells of the pancreas. But due to the possibility of her having pancreatic carcinoma, she underwent distal pancreatectomy and splenectomy with lymph node dissection. Pathologically, the tumor of the pancreatic body showed secondary changes with focal fibrosis from the localized chronic pancreatitis. PanIN-III was observed in the pancreatic duct within the tumor, and there were no cancerous findings in the 13 dissected lymph nodes. (Korean J Med 74:310-314, 2008)
-
증 례 : 혈청 단클론단백 상승 없이 골수외 병변이 진행한 다발골수종
김설희 ( Sul Hee Kim ),지영근 ( Young Geun Jee ),여욱현 ( Wook Hyun Yeo ),손병석 ( Byeong Seok Sohn ),김성록 ( Sung Rok Kim ),김현정 ( Hyun Jung Kim ),유영진 ( Young Jin Yuh ) 대한내과학회 2016 대한내과학회지 Vol.90 No.1
다발골수종의 치료 효과 판정 및 관해 이후 추적관찰에 이용되는 단클론단백은 골수외형질세포종 부위의 재발 및 악화를 정확하게 반영하지 못할 개연성이 있다. 최근 다발골수종의 치료에 bortezomib이 도입되어 치료 반응 및 생존율의 개선이 있었으나, 골수외형질세포종을 함께 보이는 다발골수종 환자에서 치료 반응에 대한 보고는 적어 이에 대한연구가 필요해 보인다. 저자들은 VMP 항암화학 치료 이후 부분 관해를 보였으나, 골수외형질세포종의 악화에도 불구하고 혈청 단클론단백 상승이 관찰되지 않았던 환자를 경험하였고, 이후 이차 항암화학요법으로 VAD를 진행하면서 안정적인 경과를 보이는 증례를 경험하여 보고하는 바이다. A 76 year-old female who was diagnosed with multiple myeloma (IgG, lambda) had received bortezomib, melphalan and prednisolone as first-line treatment. After completing six cycles of chemotherapy, her serum monoclonal protein level decreased from 7.28 g/dL to 0.65 g/dL, indicating a partial response. However, at the next scheduled visit she complained of slowly progressing dyspnea. On chest X-ray, newly developed pleural effusion was found, and rapidly progressing extramedullary plasmacytoma was detected in the anterior mediastinum on chest computerized tomography. However, there was no change in her serum monoclonal protein level. In Korea, extramedullary involvement is encountered in 5% of patients with multiple myeloma. However, evaluation of treatment response using solely the serum monoclonal protein level may not accurately reflect disease status in these patients. (Korean J Med 2016;90:55-58)
-
증례 : 혈액종양 ; 재발한 무거대핵세포혈소판감소증의 Cyclosporine 치료
배수야 ( Soo Ya Bae ),한태희 ( Tae Hee Han ),손병석 ( Byeong Seok Sohn ),오현호 ( Hyun Ho Oh ),최성진 ( Seong Jin Choi ),박문 ( Moon Park ),유영진 ( Young Jin Yuh ) 대한내과학회 2016 대한내과학회지 Vol.90 No.3
Acquired amegakaryocytic thrombocytopenia (AAMT) is an unusual disease characterized by severe thrombocytopenia resulting from a marked decrease in bone marrow megakaryocytes. Various pathogenic mechanisms have been suggested, and several treatments have been tried, with varying outcomes. In some case reports, cyclosporine and anti-thymocyte globulin have had good clinical results in the treat of AAMT. There are few reports on the treatment of relapsed AAMT with cyclosporine. We report a patient with relapsed AAMT who was treated successfully with an additional course of cyclosporine. The initial remission was achieved with cyclosporine 4 years earlier and a second remission was induced by cyclosporine. Cyclosporine may be effective for relapsed AAMT that previously responded to cyclosporine. (Korean J Med 2016;90:258-261)
-
증례 : 혈액종양 ; 일차성 중추신경계 림프종의 경막 내 Rituximab 치료 2예
장용호 ( Yong Ho Jang ),하태환 ( Tae Hwan Ha ),김덕희 ( Deok Hee Kim ),김성록 ( Sung Rok Kim ),유영진 ( Young Jin Yuh ),손병석 ( Byeong Seok Sohn ),이혜란 ( Hye Ran Lee ) 대한내과학회 2014 대한내과학회지 Vol.87 No.2
일차성 중추 신경계 림프종(PCNSL)은 완전 관해 이후에도 재발이 흔하고 대부분 뇌연수막 전이에 의해 불량한 예후를 나타내는데 rituximab 경막 내 투여를 통해 PCNSL의 안정 병변 기간 연장 및 부작용은 거의 나타나지 않은 임상증례 2례를 경험하여 보고하며 rituximab 경막 내 투여에 대한 임상 시험 및 연구가 좀 더 필요할 수 있겠다. Primary central nervous system lymphoma (PCNSL) is an aggressive non-Hodgkin`s lymphoma (NHL), usually composed of diffuse large B-cells. Although rituximab is known for its curative effect on B-cell NHL, data on the use of intrathecal rituximab for PCNSL are limited. In this report, we present two patients showing relapsed PCNSL with lymphomatous meningitis. Both patients were refractory to conventional methotrexate-based intrathecal chemotherapy. However, after intrathecal rituximab with or without conventional intrathecal chemotherapy, both patients showed stable disease on magnetic resonance brain imaging and cerebrospinal fluid analysis. There were no serious adverse events during each of 3 and 6 cycles with intrathecal rituximab immunotherapy. (Korean J Med 2014;87:224-228)
-
오련,송은희,박기호,조오현,김탁,윤귀준,손병석,성흥섭,김미나,김양수,우준희 대한감염학회 2008 감염과 화학요법 Vol.40 No.5
Cryptococcosis is a disseminated infection caused by Cryptococcus neoformans. It usually causes pulmonary infection and meningitis in immunocompromised patients. However, osteomyelitis due to C. neoformans is extremely rare. It is generally known that cryptococcal osteomyelitis is a complication of disseminated cryptococcosis, appearing in 5-10%. We experienced a case of cryptococcal osteomyelitis with paraspinal abscess in a liver transplant patient.
KISS연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
